 |
| TheRNAblog |
Scientists have built synthetic RNA carriers from the bottom up—and one of them dramatically outperformed conventional delivery systems in laboratory experiments
For decades, biology has looked to viruses for inspiration.
Viruses are extraordinarily good at one thing: moving genetic material into cells. Their protein shells package nucleic acids, protect them from degradation, recognize cells and ultimately release genetic cargo inside them.
That ability has made viral vectors powerful tools for gene therapy.
But there is an intriguing question we rarely ask:
What if evolution did not produce the best possible RNA-delivery vehicle?
Evolution does not engineer biological systems for our purposes. It optimizes them for survival, reproduction and transmission within particular ecological environments. Features that make a virus successful in nature may therefore be unnecessary—or even undesirable—when our goal is simply to deliver therapeutic RNA into a cell.
A remarkable new study published in Nature takes this idea seriously.
Rather than modifying an existing virus, researchers used artificial intelligence-designed proteins to construct RNA delivery vehicles essentially from the bottom up.
The result was a family of what they call synthetic transfer vehicles, or STVs.
And one particular design—STV-C8—showed striking RNA-delivery performance.
Instead of copying viruses, design something new
Most viruses package their genomes inside highly organized protein structures. Despite enormous viral diversity, many capsids converge on a relatively small number of architectural principles, particularly icosahedral and helical structures.
But modern generative protein-design systems can explore structural possibilities that evolution may never have sampled.
The researchers therefore asked whether AI-designed protein assemblies with unusual geometries could serve as the structural foundation for completely new RNA carriers.
Using protein assemblies produced with RFdiffusion, they combined synthetic protein structures with biological components responsible for several essential tasks:
binding cellular membranes,
promoting vesicle budding,
binding and packaging RNA, and
facilitating entry into recipient cells.
More than 100 different synthetic transfer vehicle designs were ultimately examined.
The researchers did not simply ask whether a particle formed. Their screening system evaluated several steps independently, including particle release, cellular uptake and successful expression of the delivered RNA.
That distinction is important.
A delivery particle can enter a cell without delivering useful RNA. Likewise, it can package RNA efficiently yet fail to release its cargo where it matters.
The researchers were therefore effectively optimizing the complete delivery process.
The surprise: the best architecture did not look like a virus
One might expect an artificial system that performs virus-like functions to work best when it resembles a viral capsid.
That was not what happened.
Synthetic assemblies containing dihedral and cyclic symmetries often performed better than the more virus-like icosahedral designs.
The eventual lead platform contained an AI-designed protein assembly called HE0690, organized with C8 cyclic symmetry.
After optimizing additional components—including a membrane-binding domain—the researchers created the system they named STV-C8.
Its architecture combines several modules:
membrane binding → budding → RNA recognition → synthetic protein assembly
This modular organization is one of the most interesting aspects of the work. Instead of treating the delivery vehicle as an indivisible biological object, the researchers treated it more like an engineered platform whose components could be independently optimized.
STV-C8 delivered RNA with extraordinary efficiency
When characterized experimentally, STV-C8 showed strong enrichment of its intended cargo RNA and formed membrane-bound vesicles typically around the nanoscale range expected for biological delivery particles.
But its delivery efficiency attracted the most attention.
When STV-C8 was compared with several genetically encoded RNA-delivery systems, it produced higher expression of the delivered RNA across the tested cell types.
The researchers then compared it with lipid nanoparticles containing ALC-0315, the ionizable lipid used in the Pfizer–BioNTech COVID-19 vaccine formulation.
In their experimental system, STV-C8 produced a more than 1,000-fold higher transfection rate than the tested LNP formulation.
Even more strikingly, the amount of STV-C8-delivered mRNA required to obtain comparable protein expression was reported to be more than 10,000-fold lower than the amount required with the LNP system.
Those numbers require careful interpretation. They come from particular experimental conditions and should not be interpreted as proof that STV-C8 is universally 1,000 or 10,000 times better than every clinically optimized LNP formulation.
Nevertheless, they demonstrate something important:
the delivery architecture has considerable potential.
RNA cargo without the usual capsid-size constraint
Conventional viral vectors frequently face another problem: cargo capacity.
There is only so much genetic material that can fit inside a closed viral capsid.
STV-C8 may operate differently.
The researchers proposed that RNA may associate with the outside surface of the synthetic protein oligomer while remaining protected inside the surrounding membrane vesicle.
If that model is correct, RNA does not have to fit inside a rigid protein shell.
Experimentally, the researchers tested RNA cargos ranging from approximately 1 to 10 kilobases and observed effective delivery throughout that range, with no obvious packaging limit within the tested window.
That could be particularly useful for large messenger RNAs encoding genome editors, transcription factors or other therapeutic proteins.
The researchers also programmed where the particles go
Efficiency alone is not enough for RNA medicine.
A therapeutic RNA carrier must ideally deliver its cargo to the right cell.
The researchers therefore added another layer of AI-guided design.
Computationally designed peptide binders targeting EGFR or IL-7Rα were incorporated into the particles. These molecules acted as targeting modules, enabling preferential uptake by cells expressing the corresponding receptor.
Cells expressing both receptors could even respond to vehicles carrying both targeting modules, suggesting that future delivery systems might use combinations of recognition molecules to refine tissue or cell specificity.
This creates a compelling engineering concept:
AI designs the carrier.
AI can help design the targeting ligand.
RNA provides the therapeutic program.
The delivery system becomes increasingly programmable.
Not just reporter RNA
Demonstrating GFP expression is useful for developing a platform, but therapeutic relevance requires considerably more.
The researchers therefore tested STV-C8 with a surprisingly broad range of RNA cargos.
They delivered messenger RNA encoding the transcription factor ASCL1 into primary mouse astrocytes and detected ASCL1 expression in more than 30% of cells.
They delivered Cas9 mRNA and guide RNAs designed to edit the dystrophin gene.
They also packaged the RNA-targeting CRISPR nuclease Cas13d together with a guide targeting SARS-CoV-2.
When this antiviral system was delivered into human iPSC-derived lung cells subsequently infected with SARS-CoV-2-GFP, viral replication was almost completely suppressed in the experimental model.
The important message is not simply that STV-C8 delivers RNA.
It appears capable of delivering functional molecular programs.
From cell culture to animals
The study went further.
After intravenous administration of STV-C8 carrying EGFP mRNA in mice, the researchers performed whole-body clearing and high-resolution imaging to determine where expression occurred.
Interestingly, they observed strong expression predominantly in the lung, rather than the liver—the organ that commonly accumulates many conventional lipid nanoparticles.
The study reported no detectable immunological or toxicological effects following systemic administration under the tested conditions.
This natural lung tropism may itself become useful, although whether it remains desirable would depend on the therapeutic application.
For other diseases, targeting will have to be redesigned.
A test case: Duchenne muscular dystrophy
One of the most ambitious demonstrations involved Duchenne muscular dystrophy (DMD).
DMD is caused by mutations that disrupt the dystrophin gene and progressively destroy skeletal and cardiac muscle function.
For some mutations, removal of particular exons can restore the dystrophin reading frame.
The researchers therefore packaged CRISPR–Cas9 mRNA together with guide RNAs targeting regions surrounding dystrophin exon 51.
In cultured porcine fibroblasts, they observed approximately 40% deletion of the targeted region.
They then injected STV-C8 containing Cas9 and guide RNAs directly into pig muscle and confirmed deletion of exon 51.
Finally, STV-C8-mediated editing was tested in skeletal muscle cells derived from patients with DMD, where deletion of exon 51 restored the dystrophin open reading frame.
This does not mean STV-C8 is ready to treat DMD.
The authors themselves point out an important limitation: local intramuscular injection is not a practical treatment for a disease affecting muscles throughout the body.
Systemic muscle targeting remains a major challenge.
Nevertheless, successful delivery of a functional genome-editing system into a large-animal tissue moves the platform well beyond a simple proof-of-concept nanoparticle.
Why this study matters beyond RNA delivery
Perhaps the most important idea in this paper is broader than STV-C8 itself.
Biotechnology has traditionally engineered biological systems by starting with something evolution already produced and then modifying it.
A virus becomes a gene-delivery vector.
A bacterial nuclease becomes CRISPR technology.
A naturally occurring antibody becomes a therapeutic antibody.
Generative AI introduces another possibility:
Start with the function we want and search protein space for structures that evolution never created.
That changes the engineering philosophy.
Instead of asking:
“Which natural protein can we modify?”
we can increasingly ask:
“What protein architecture should exist to perform this function?”
The researchers argue that RNA transfer vehicles are particularly suitable for current generative protein-design systems because these algorithms are already very good at generating stable, symmetric protein assemblies. Designing highly dynamic enzymes remains considerably harder.
Important questions remain
Despite the impressive results, several hurdles separate STV-C8 from clinical translation.
Long-term safety and immunogenicity will need much more extensive evaluation.
Manufacturing at therapeutic scale will have to be developed.
Pharmacokinetics, stability, dosing and repeat administration require careful study.
Targeting must become sufficiently precise to avoid unwanted tissues.
The reliance on additional fusogenic components also needs to be considered when translating the technology into therapeutic formulations.
And most importantly, the exceptional efficiency reported in these experimental comparisons will need validation across additional delivery systems, animal models and clinically relevant dosing conditions.
Even the DMD experiment illustrates the difference between demonstrating molecular editing and creating a practical therapy. The authors explicitly acknowledge that direct intramuscular administration does not solve the systemic delivery problem and identify comparative performance, targeting and cell-type specificity as areas requiring future study.
A new chapter for synthetic biology
The significance of STV-C8 is therefore not that lipid nanoparticles or viral vectors are suddenly obsolete.
It is that the design space for biological delivery systems may be far larger than we previously imagined.
Evolution gave us viruses.
Chemistry gave us lipid nanoparticles.
Synthetic biology is now beginning to give us something different:
delivery vehicles whose fundamental architecture can be computationally invented.
STV-C8 is an early example of what happens when generative AI, protein engineering, RNA biology and gene editing converge.
And perhaps the most provocative lesson from this work is simple:
Nature does not necessarily contain every useful biological machine. Some of them may have to be designed.
Original research
Schuhmacher, M. K., Gruber, C., Lang, C. M. R. et al. Creating bottom-up RNA transfer vehicles from synthetic protein assemblies. Nature (2026). DOI: 10.1038/s41586-026-10952-3.
No comments:
Post a Comment